In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Confirmed: Siemens Aims For H1 2018 IPO for Healthineers

Executive Summary

Siemens is planning to spin out its Healthineers business in an IPO slated for the first half of next year, the German conglomerate has confirmed. The move will give the health care business "the required currency and entrepreneurial flexibility" to grow in a fundamentally attractive market, it said. The announcement was made in conjunction with the group's reporting of its third quarter results for fiscal 2017, in which solid diagnostics imaging sales helped to boost the top line for Healthineers.

You may also be interested in...

Clinica 100: Top Spot Soon Within Medtronic’s Grasp; More Change In 2016

Medtronic may have pulled off the biggest merger in medtech history, but Johnson & Johnson has once again held on to its number one spot in this year’s Clinica 100 league table – but only just. With J&J having done more streamlining in 2015 and Medtronic in line to benefit from the addition of Covidien sales for a full fiscal year, the next edition of our league table in 2016 will very likely see a new leader.

Covidien - world's fifth largest healthcare products company - begins trading

Covidien, the former healthcare division of the $41bn conglomerate Tyco International, made its debut as an independent company on the New York Stock Exchange and in Bermuda on Monday (July 2). The move comes nearly a year after Tyco International first revealed it was considering splitting up into three separate and more manageable businesses.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts